Global Longevity Intelligence
Track companies, interventions, trials, biomarkers, clinics, deals, and regulation through an evidence-first scorecard model.
BioAge Labs is a public clinical-stage biopharmaceutical company that describes a human-aging-biology platform. This source-reviewed profile treats BioAge as a company-and-pipeline intelligence profile; BGE-102, APJ, and STRIDES context remain company-reported or registry-backed, not clinical outcome proof.
MILES was a small randomized crossover study in older adults with impaired glucose tolerance that examined transcriptomic and metabolic readouts. This source-reviewed record treats MILES as a narrow trial/evidence record, not as proof of broad metformin longevity benefit.
Umbrella biomarker-signal record covering IMM-AGE, iAge, IMMAX, sc-ImmuAging, and related immune-clock approaches as distinct research-stage signals. It compares model-development, association, and trial-readiness evidence while keeping diagnostic, consumer-test, and clinical-utility claims out of scope.
Research-stage biomarker category covering DNA methylation clocks and pace-of-aging measures. Not diagnostic or prescriptive.
Regulatory watch for longevity, regenerative, and clinic advertising claim-risk patterns. Not legal advice.
Regulatory watch for consumer biomarker and direct-to-consumer test claim-risk context. Not legal advice.
LN Pro